These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 18845489)

  • 21. Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
    Vincenti D; Piselli P; Solmone M; D'Offizi G; Capobianchi MR; Menzo S
    Antiviral Res; 2017 Jul; 143():62-68. PubMed ID: 28322924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations].
    Juszczyk J; Boroń-Kaczmarska A; Cianciara J; Flisiak R; Gładysz A; Halota W; Kryczka W; Malkowski P; Pawlowska M; Simon K;
    Pol Merkur Lekarski; 2010 Aug; 29(170):103-6. PubMed ID: 20842822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chronic hepatitis B: current therapy].
    Buffet C
    Bull Acad Natl Med; 2008 Nov; 192(8):1625-37; discussion 1638-9. PubMed ID: 19445377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
    Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
    Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Looking to the future: new agents for chronic hepatitis B.
    Dienstag JL
    Am J Gastroenterol; 2006; 101 Suppl 1():S19-25. PubMed ID: 16448448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
    Tornai I
    Orv Hetil; 2011 May; 152(22):869-74. PubMed ID: 21565754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
    Mirandola S; Campagnolo D; Bortoletto G; Franceschini L; Marcolongo M; Alberti A
    J Viral Hepat; 2011 Jul; 18(7):e212-6. PubMed ID: 21692935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of treatments for chronic hepatitis B.
    Wiens A; Lenzi L; Venson R; Pedroso ML; Correr CJ; Pontarolo R
    Braz J Infect Dis; 2013; 17(4):418-26. PubMed ID: 23849851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies.
    Kim HS; Yim HJ; Jang MK; Park JW; Suh SJ; Seo YS; Kim JH; Kim BH; Park SJ; Lee SH; Kim SG; Kim YS; Lee JI; Lee JW; Kim IH; Kim TY; Kim JW; Jeong SH; Jung YK; Park H; Hwang SG;
    World J Gastroenterol; 2015 Oct; 21(38):10874-82. PubMed ID: 26478678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Protocol for the antiviral therapy of chronic hepatitis B].
    ;
    Orv Hetil; 2008 Dec; 149(49):2341-3. PubMed ID: 19042187
    [No Abstract]   [Full Text] [Related]  

  • 32. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients.
    Dienstag JL; Wei LJ; Xu D; Kreter B
    Clin Drug Investig; 2007; 27(1):35-49. PubMed ID: 17177578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
    Rijckborst V; Sonneveld MJ; Janssen HL
    Aliment Pharmacol Ther; 2011 Mar; 33(5):501-13. PubMed ID: 21198707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabine-containing regimen.
    Mata-Marín JA; Mata-Marín LA; Arroyo-Anduiza CI; Huerta-García G; Sandoval-Ramirez JL; Manjarrez-Tellez B; Gaytán-Martínez JE
    Hepatogastroenterology; 2014; 61(133):1187-91. PubMed ID: 25436280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
    de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic hepatitis B: a wider range of therapeutic options.
    Prescrire Int; 2007 Aug; 16(90):157-62. PubMed ID: 17724844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA.
    Lu J; Zhang S; Liu Y; Du X; Ren S; Zhang H; Ma L; Chen Y; Chen X; Shen C
    Liver Int; 2015 Jun; 35(6):1692-9. PubMed ID: 25438657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment recommendations of chronic hepatitis B. Did the world escape us?].
    Flisiak R; Jaroszewicz J
    Przegl Epidemiol; 2008; 62(1):133-8. PubMed ID: 18536235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
    Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.